TapImmune Inc. is a biotechnology company headquartered in Bellevue, Washington. They specialize in the development of immunotherapeutic vaccines for cancer and infectious diseases. Their core business focus is on emerging technologies based on cellular immunology and genetic understanding of the cause and potential novel treatments of disease.

TapImmune Inc.’s lead product is the TAP vaccine. It performs a key step in moving characteristic markers called antigens to the surfaces of cells. Without TAP, there are no cancer markers. Therefore, the immune system fails to spot the rogue cells and the cancerous cells can grow undetected. In addition, the TAP molecule works as an adjuvant (accelerant) to enhance targeted vaccines against infectious diseases.

The Company is developing AdhTAP for the commencement of toxicology studies leading to the initiation of Phase I clinical trials. The expectation is that the global vaccine market will grow from $13 billion in 2007 to $21 billion

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Monday October 12, 2009

DrStockPick.com Stock Report!

AAPL, PWRM, GOOG, CSRH, C, CVAT, INTC, AQNM, IBM

**************************************************************

AAPL, Apple Inc. and GOOG, Google Inc.

AAPL and its wholly owned subsidiaries design, manufacture, and market personal computers, portable digital music players, and mobile communication devices, and sell various related software, services, peripherals, and networking solutions.

GOOG, a technology company, maintains index of Websites and other online content for users, advertisers, Google network members, and other content providers.

Arthur Levinson has resigned from GOOG’s board, averting a potential showdown with government regulators over his overlapping job as a director for computer and gadget maker

...

The sequencing of the human genome has resulted in the emergence of an enormously important new branch in the biotechnological sciences. The most common terms for this field are bioinformatics or computational biology.

You may have read about the discovery, recently, of a new and radically more effective mosquito repellent. Based on molecules found in black pepper, it was not discovered using traditional laboratory methods. Instead, it came about through computer simulations based on knowledge of mosquito cell biology. This is just the tip of the bioinformatics iceberg.

Until recently, cell biology has been something of a “black box.” We could observe how cells functioned, but had little insight into the actual mechanisms. Now, though, scientists are learning how cells work on the molecular level.

Using mathematical models and new technologies for detecting molecular processes, researchers are extracting raw data from DNA and modeling the ways genes work and interact. To understand this

...

Currently, medicine is, to a large degree, a “one size fits all” proposition. Doctors watch for adverse effects and check personal and family histories. Medical technologies, however, are designed for the general population, not individuals. That’s going to change.

Moreover, there will be huge profit opportunities, in many enabling technologies, for those who invest accordingly. And today I’m going to tell you about a company that will hand you your best chance to make a transformational fortune.

We know that many current treatments work on some people, yet not others. Some drugs are safe for many people, but have dangerous side effects for others. This is because all of us have individual differences in our genetic code based on heredity and environment. Even slight differences can lead to very different reactions to medications.

This has created serious regulatory problems. Drugs are denied regulatory approval not because they do not work, but because some

...

Bond bubble remerges… details behind the gov’s latest debt struggle… The slow demise of snail mail… USPS forecasts record losses… Customized drugs: Patrick Cox on a breakthrough set to revolutionize health care… Bill Jenkins with another sign the euro is overvalued… his price targets below…

Just when you thought the bond bubble was being saved for another day…

The government managed to auction $39 billion worth of 5-year debt yesterday… barely. Wednesday’s debt sale drew a bid-to-cover ratio of 1.92, the lowest investor demand since September 2008. Low demand forced Uncle Sam to jack up interest rates at the last minute in two separate bond auctions this week — yesterday’s sale and Tuesday’s $42 billion auction of 2-year notes.

So what’s an indebted government to do? Manipulate the market, of course. Bond yields have given back yesterday’s spike partly thanks to the Federal Reserve, which bought $3

...

Resource legend tips his hat to three soon-to-bubble sectors… The housing market has “bottomed out” says PNC… our gentle retort… Alan Knuckman with an economic indicator far superior to unemployment: chicken sales… Our panel of “whiskey shooters” on the worst-case scnerio… how to get out of Dodge if the dollar collapses… Britian now REALLY in crisis… recession, taxes cause wave of pub shutdowns…

Let’s make some trades this morning. We asked Rick Rule, a living legend here in Vancouver, what’s the next bubble market? “The Canadian market does not care about small oil and gas companies,” he told us yesterday. “Which means that small Canadian O&G companies are selling for 50-60% of net asset value. They are very, very, very cheap. They are unloved, with no finance options and no trading liquidity… and I love that. This value is free. There will be much money made in small-cap

...

For Immediate Release

Chicago, IL - April 27, 2009 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Lockheed Martin Corp (LMT), Schlumberger, Ltd. (SLB), Halliburton's (HAL), deCODE genetics, Inc. (DCGN) and Celera Corp. (CRA).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579.

Here are highlights from Friday's Analyst Blog:

Lockheed Beats & Ups Guidance

Lockheed Martin Corp (LMT) reported a 1st quarter 2009 profit of $666 million, down 9% from $730 million in the 1st quarter of 2008.

On a per-share basis, the reported result was $1.68 per diluted share, down 4% from $1.75 per diluted share

...

 Yesterday (Thursday), deCODE genetics, Inc. (DCGN) announced that the company signed an agreement with Celera Corp. (CRA). Pursuant to the agreement, deCODE granted Celera non-exclusive worldwide licenses to deCODE's genetic markers for increased risk of major cardiovascular and metabolic diseases, including heart attack, stroke, atrial fibrillation (AF) and type II diabetes. These markers can be incorporated into laboratory tests for assessing and managing individual risk of these diseases.The deCODE markers include single letter variations in the human genome (SNPs) on chromosome 9p21 linked to increased risk of heart attack and aortic aneurysm, SNPs on chromosome 4q25 conferring risk of AF and stroke, and SNPs in the TCF7L2 gene linked to increased risk of type II diabetes. Studies by deCODE and independent academic groups have demonstrated the utility of testing for these markers to better understand individual risk and to inform more effective and personalized prevention ...